Larger reduction seen in consumption; evidence insufficient to assess potential modifiers for food consumption
Fewer Bleeding Events Seen With Abelacimab Than Rivaroxaban in A-Fib
Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke